#### 505609103 08/06/2019

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5655904

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

### **CONVEYING PARTY DATA**

Name	Execution Date
HEALTH INNOVATION VENTURES B.V.	05/22/2019

### **RECEIVING PARTY DATA**

Name:	CONVERT PHARMACEUTICALS SA	
Street Address:	QUAI BANNING 6	
City:	LIEGE	
State/Country:	BELGIUM	
Postal Code:	4000	

### **PROPERTY NUMBERS Total: 4**

Property Type	Number
Application Number:	16251789
Patent Number:	10202408
Patent Number:	9873710
Patent Number:	9505791

### **CORRESPONDENCE DATA**

Fax Number: (312)577-7007

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3125777000

Email: itorres@fitcheven.com

FITCH EVEN TABIN & FLANNERY LLP **Correspondent Name:** 

120 SOUTH LASALLE STREET Address Line 1:

Address Line 2: **SUITE 2100** 

Address Line 4: CHICAGO, ILLINOIS 60603-3406

ATTORNEY DOCKET NUMBER:	20595-144727-US
NAME OF SUBMITTER:	CALISTA J. MITCHELL
SIGNATURE:	/Calista J. Mitchell/
DATE SIGNED:	08/06/2019

**Total Attachments: 2** 

source=Assignment-Convert#page1.tif source=Assignment-Convert#page2.tif

> **PATENT** REEL: 049979 FRAME: 0912 505609103

### **ASSIGNMENT and TRANSFER**

#### The undersigned

#### Health Innovation Ventures B.V.

of Oxfordlaan 55, Biopartner gebouw, 6229 EV Maastricht, The Netherlands

a company organised and existing under the laws of The Netherlands, represented by L.J.M. Klaasse-van Remortel, in the capacity of CEO, singly authorised to represent said company, hereinafter indicated as ASSIGNOR

#### And

#### Convert Pharmaceuticals SA

of Quai Banning 6, 4000 Liège, Belgium

a company organised and existing under the laws of Belgium, represented by Dr. Mariola Soehngen, in the capacity of Managing Director, singly authorised to represent Convert Pharmaceuticals SA, hereinafter indicated as **ASSIGNEE** 

Declare and agree as follows concerning the patents and patent applications mentioned on the attached schedule:

- 1. ASSIGNOR has, on the basis of purchase, by written agreement assigned and transferred, and insofar as necessary herewith assigns and transfers, to ASSIGNEE all its rights and obligations regarding the above-mentioned patents/patent applications and the inventions described therein, including any and all priority rights of the said patents/patent applications and including any and all divisional patent applications and continuations thereof, and including all causes of action, whether known or unknown, or whether:
- (1) Previously filed in court and currently pending or (2) filed with a court in the future and other enforcement rights under or on account of the said patents/patent applications, including, without limitation, all causes of action and other enforcement rights for:
- (i) Damages for past, current, and future infringement;
- (ii) Injunctive relief, and

ASSIGNOR

L.J.M. Klaasse-van Remortel

- (iii) Any other remedies of any kind for past, current, and future infringement.
- 2. ASSIGNEE has by written agreement accepted, and insofar as necessary herewith accepts, this assignment and transfer with all rights and obligations.
- 3. For this assignment and transfer, ASSIGNEE has paid to ASSIGNOR the sum of ten (10) Euros, the receipt of which is hereby acknowledged by ASSIGNOR.
- 4. ASSIGNOR and ASSIGNEE wish, request and authorize that this assignment and transfer are recorded in the applicable registers, and that ASSIGNEE is registered as patentee/applicant.

Thus agreed and signed in multiple originals.

(Signature)

(Name)

Dr. Mariola Soehngen,

ASSIGNEE

(City, date)

Witnesses

(Witness signature)

(Witness name)

(Witness address)

c/o Quai Banning 6, Liège, BE

Dr Ame Heverick

V.O. ref. AP109676NL01

c/o Oxfordlaan 55, Maastricht, NL

S.W.G. Hantiens

PATENT REEL: 049979 FRAME: 0913

## SCHEDULE OF PATENTS AND PATENT APPLICATIONS:

Novel prodrugs and methods of	PCT	PCT/NZ2013/000150 (claiming
use thereof		priority from NZ20120602004)
Novel prodrugs and methods of use thereof	Australia	2013306514 (granted as AU2013306514B)
Novel prodrugs and methods of use thereof	Canada	Pending as CA 2,886,574
Novel prodrugs and methods of use thereof	China	201380055423.7 (granted as CN105051004B)
Novel prodrugs and methods of use thereof	China	Pending as 201711060834.1
Novel prodrugs and methods of use thereof	European Patent Organization	Pending as 13831349.9
Novel prodrugs and methods of use thereof	United States of America	14/423,359 (granted as US 9,505,791)
Novel prodrugs and methods of use thereof	United States of America	15/339,041 (granted as US 9,873,710)
Novel prodrugs and methods of use thereof	United States of America	15/877,103 (granted as US 1,020,208)
Novel prodrugs and methods of use thereof	United States of America	Pending as 16/251,789

Dated and initaled by ASSIGNOR

(Signature)

A. C. O. ...

Dated and initaled by ASSIGNEE

L.J.M. Klaasse-van Remortel

(Name)

Dr. Mariola Soehngen,

(City, date)

V.O. ref. AP109676NL01

**RECORDED: 08/06/2019** 

PATENT REEL: 049979 FRAME: 0914